文献速递糖尿病肥胖与代谢综合征

2001至2018年英格兰糖尿病患者与非糖尿病患者主要死因趋势:基于初级保健记录关联的流行病学分析

Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-02-04

该研究基于英格兰临床实践研究数据链(CPRD)2001至2018年313 907例糖尿病患者及其匹配的非糖尿病对照,采用离散泊松回归估计全因及12类死因的年度死亡率。糖尿病患者总死亡率男性下降32%、女性下降31%,血管性死亡大幅减少使癌症成为糖尿病患者及糖尿病相关超额死亡的首位死因,痴呆和肝病死亡则上升。

要点

  • 糖尿病患者总死亡率男性下降32%、女性下降31%,与非糖尿病者的差距持续存在。
  • 血管性死亡大幅下降,癌症成为糖尿病患者死亡及糖尿病相关超额死亡的首位原因。
  • 痴呆和肝病死亡在糖尿病人群和非糖尿病人群中均上升。

核心结论

  • 糖尿病患者血管性死亡下降伴随死因多样化,癌症成为糖尿病相关死亡的首位贡献者。
  • 临床和预防策略需反映这一趋势以降低糖尿病患者的超额死亡风险。

研究设计与样本

  • 基于CPRD初级保健记录的流行病学分析,纳入2001至2018年313 907例糖尿病患者,并链接英国国家统计局死亡数据。
  • 构建重复横断面与纵向随访结合的混合患病率与发病率研究人群,采用离散泊松回归估计年度死亡率。
  • 从同一数据集中按年龄和性别1:1匹配非糖尿病个体并估计其死亡率。

主要发现

  • 2001年1月1日至2018年10月31日,确诊糖尿病男性总死亡率从40·7/1000人年降至27·8/1000人年,女性从42·7/1000人年降至29·5/1000人年。
  • 确诊糖尿病男性总死亡率下降32%,女性下降31%;非糖尿病个体呈相似下降,两者死亡率差距维持。
  • 12类死因中10类死亡率下降,痴呆和肝病死亡在糖尿病人群和非糖尿病人群中均上升。
  • 血管性疾病死亡大幅下降,使癌症成为确诊糖尿病患者死亡及糖尿病与非糖尿病死亡差距的首位贡献者。

临床怎么用

  • 糖尿病管理除继续控制血管风险外,需关注癌症、痴呆和肝病等死因的预防与早期发现。
  • 临床和预防策略应针对死因多样化趋势调整,以降低糖尿病患者的超额死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of diabetes has increased in the UK and other high-income countries alongside a substantial decline in cardiovascular mortality. Yet data are scarce on how these trends have changed the causes of death in people with diabetes who have traditionally died primarily of vascular causes. We estimated how all-cause mortality and cause-specific mortality in people with diabetes have changed over time, how the composition of the mortality burden has changed, and how this composition compared with that of the non-diabetes population. METHODS: In this epidemiological analysis of primary care records, we identified 313 907 individuals with diabetes in the Clinical Practice Research Datalink, a well described primary care database, between 2001 to 2018, and linked these data to UK Office for National Statistics mortality data. We assembled serial cross sections with longitudinal follow-up to generate a mixed prevalence and incidence study population of patients with diabetes. We used discretised Poisson regression models to estimate annual death rates for deaths from all causes and 12 specific causes for men and women with diabetes. We also identified age-matched and sex matched (1:1) individuals without diabetes from the same dataset and estimated mortality rates in this group. FINDINGS: Between Jan 1, 2001, and Oct 31, 2018, total mortality declined by 32% in men and 31% in women with diagnosed diabetes. Death rates declined from 40·7 deaths per 1000 person-years to 27·8 deaths per 1000 person-years in men and from 42·7 deaths per 1000 person-years to 29·5 deaths per 1000 person-years in women with diagnosed diabetes. We found similar declines in individuals without diabetes, hence the gap in mortality between those with and without diabetes was maintained over the study period. Cause-specific death rates declined in ten of the 12 cause groups, with exceptions in dementia and liver disease, which increased in both populations. The large decline in vascular disease death rates led to a transition from vascular causes to cancers as the leading contributor to death rates in individuals with diagnosed diabetes and to the gap in death rates between those with and without diabetes. INTERPRETATION: The decline in vascular death rates has been accompanied by a diversification of causes in individuals with diagnosed diabetes and a transition from vascular diseases to cancers as the leading contributor to diabetes-related death. Clinical and preventative approaches must reflect this trend to reduce the excess mortality risk in individuals with diabetes. FUNDING: Wellcome Trust.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Pearson-Stuttard J, Bennett J, Cheng YJ, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021. PMID: 33549162. doi:10.1016/S2213-8587(20)30431-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。